R Stahel
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
Gachechiladze M, Überall I, Skanderová D, Matchavariani J, Ibrahim M, Shani I, Smičková P, Kolek V, Cierna L, Kleine-Tebbe J, Stahel R, Joerger M, Soltermann A, Škarda J. LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma. Lung Cancer 2021; 156:129-135.
15.04.2021LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
15.04.2021Lung Cancer 2021; 156:129-135
Gachechiladze Mariam, Überall Ivo, Skanderová Daniela, Matchavariani J, Ibrahim M, Shani Ilay, Smičková Petra, Kolek Vítězslav, Cierna L, Kleine-Tebbe Jörg, Stahel R, Joerger M, Soltermann A, Škarda Josef
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer
Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus P, Sorensen J, Felix E, Panel members. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol 2011; 22:1973-1980.
01.09.20111st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer
01.09.2011Ann Oncol 2011; 22:1973-1980
Stahel R, Thatcher N, Früh Martin, Le Péchoux C, Postmus P E, Sorensen J B, Felix E, Panel members
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011; 22:1507-1519.
01.07.2011Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
01.07.2011Ann Oncol 2011; 22:1507-1519
Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel members
Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4484.
01.01.2010Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98
01.01.2010J Clin Oncol 2010; 28:4480-4484
Martinelli G, Zucca E, Dietrich P Y, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess Urs, Cerny Thomas, Utiger U, Schmitz S F, Ghielmini M
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British journal of cancer 2006; 94:1099-106.
24.04.2006Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
24.04.2006British journal of cancer 2006; 94:1099-106
Betticher D C, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny Thomas, Ris H-B, Stahel R, Spiliopoulos A, Roth A D, Hsu Schmitz S-F, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R A, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK)
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Franscini L, Salles G, Rufibach K, Schmitz S. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1675-82.
01.10.2005Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
01.10.2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1675-82
Ghielmini M, Cerny Thomas, Wernli M, Ketterer N, Lohri A, Stahel R, Martinelli G, Fey M, Cogliatti S, Léger-Falandry C, Leoncini-Franscini L, Salles G, Rufibach K, Schmitz S-F Hsu
Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO)
Fogliata A, Schefer H, Curti G, Schott A, Zenklusen H, Roth A, Morel P, Gertsch P, Gervaz P, Davis J, Székely G, Burger C, Huser M, Kolotas C, Thalmann G, Guillou L, Jichlinski P, von Briel C, Beer K, Miralbell R, Escudé L, Mollà M, Nouet P, Rouzaud M, Mini R, Kemmerling L, Vetterli D, Lütolf U, Ulmer U, Oehler C, Weber D, Bolsi A, Lomax A, Timmermann B, Goitein G, Verwey J, Pedroni E, Rutz H, Lomax A, Weber D, Luthi F, Pasche P, Bentzen S, Khalil A, Dubois J, Pica A, Stupp R, Stadelmann O, Allaoua M, Kebdani T, Slosman D, Dische S, Cummings B, Van den Bogaert W, Horiot J, Saunders M, Isaak B, Pesce G, Popowski Y, Tebeu P, Matzinger O, Betz M, Corminboeuf F, Bouville S, Özsoy O, Bigler R, Vees H, Girardet C, Abdou M, Huguenin P, Verkooijen H, Bouchardy C, Franzetti A, Richetti A, Presilla S, Motta M, Valley J, Bressan S, Bulling S, Pache G, Merçay A, Major A, Usel M, Ludicke F, Rufibach K, Ries G, Coucke P, Wang H, Pasche G, Do H, Balmer A, Munier F, Jargy C, Dipasquale G, Born E, Szczerba D, Hueber P, Hafner H, Cozzi L, Moeckli R, Boehringer T, Collen T, Laluhovà D, Allemann K, Bründler M, Krayenbühl J, Schoenmaker E, Norton I, Baumert B, Rutz H, Pedroni E, Lin S, Coray A, Nicolini G, Vees H, Martineau P, Gourgou S, Zouhair A, Ozsahin M, Cunat S, Larbouret C, Azria A, Bonny C, Hofstetter B, Tenzer A, Krek W, Lutters G, Evans D, Romieu G, Bodis S, Stahel R, Weder W, Jerman M, Schneiter D, Jörger M, Lardinois D, Taverna C, Kestenholz P, Heuberger J, Pèlegrin A, Pujol P, Zimmer Y, Greiner R, Gruber G, Ametamey S, Bodis S, Zingg D, Jochum W, Vuong V, Honer M, Riesterer O, Mhawech P, Verdan C, Tschanz E, Dulguerov P, Ares C, Pruschy M, Inteeworn N, Stalder D, Streit B, Ganapathipillai S, Aebersold D, Berthou S, Kaser-Hotz B, Gassmann M, Rohrer Bley C, Wergin M, Roos M, Höpfl G, Ohlerth S, Allal A, Behrensmeier F, Thürlimann B, Carbone A, Crivellari D, Collins J, Gol-Ouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, Simoncini E, Fey M, Bortoluzzi L, Weitzel M, Kranzbuehler H, Becker M, Taussky D, Azria D, Mirimanoff R, Kramar A, Jeanneret Sozzi W, Goldhirsch A, Coates A, Gelber R, Ueltschi G, Lippold B, Kranzbühler H, Bernier J, Studer G, Landmann C, Mahler F, Greiner R, Taverna C, Stanek N, Ciernik I, Friedrich E, Beer K, Balmer Majno S, Hügli A, Gallino A, Juelke P, Pajic B, Curschmann J, Bieri S, Luthi J, Suleiman M, Bargetzi M, Notter M, Thum P, Resink T, Erne P, Jamshidi P, Hafner H, Mach N. Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO). Strahlenther Onkol 2004; 180 Suppl 1:89-108.
01.06.2004Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO)
01.06.2004Strahlenther Onkol 2004; 180 Suppl 1:89-108
Fogliata A, Schefer H, Curti G, Schott A, Zenklusen H, Roth A D, Morel Ph, Gertsch P, Gervaz P, Davis J B, Székely G, Burger C, Huser M, Kolotas C, Thalmann G, Guillou L, Jichlinski P, von Briel C, Beer K, Miralbell R, Escudé L, Mollà M, Nouet P, Rouzaud M, Mini R, Kemmerling L, Vetterli D, Lütolf U M, Ulmer U, Oehler C, Weber D, Bolsi A, Lomax A, Timmermann B, Goitein G, Verwey J, Pedroni E S, Rutz H P, Lomax A J, Weber D C, Luthi F, Pasche P, Bentzen S M, Khalil A A, Dubois J B, Pica A, Stupp R, Stadelmann O, Allaoua M, Kebdani T, Slosman D O, Dische S, Cummings B J, Van den Bogaert W, Horiot J C, Saunders M I, Isaak B, Pesce G, Popowski Y, Tebeu P, Matzinger O, Betz M, Corminboeuf F, Bouville S, Özsoy O, Bigler R, Vees H J, Girardet C, Abdou M, Huguenin P, Verkooijen H, Bouchardy C, Franzetti A, Richetti A, Presilla S, Motta M, Valley J F, Bressan S, Bulling S, Pache G, Merçay A, Major A, Usel M, Ludicke F, Rufibach K, Ries G, Coucke P, Wang H, Pasche G, Do H P, Balmer A, Munier F, Jargy C, Dipasquale G, Born E J, Szczerba D, Hueber P, Hafner H P, Cozzi L, Moeckli R, Boehringer T, Collen T, Laluhovà D, Allemann K, Bründler M-A, Krayenbühl J, Schoenmaker E, Norton I A, Baumert B G, Rutz H, Pedroni E, Lin S, Coray A, Nicolini G, Vees H, Martineau P, Gourgou S, Zouhair A, Ozsahin M, Cunat S, Larbouret C, Azria A, Bonny C, Hofstetter B, Tenzer A, Krek W, Lutters G, Evans D B, Romieu G, Bodis St, Stahel R, Weder W, Jerman M, Schneiter D, Jörger Markus, Lardinois D, Taverna Ch, Kestenholz P, Heuberger J, Pèlegrin A, Pujol P, Zimmer Y, Greiner R H, Gruber G, Ametamey S, Bodis S, Zingg D, Jochum Wolfram, Vuong V, Honer M, Riesterer O, Mhawech P, Verdan C, Tschanz E, Dulguerov P, Ares C, Pruschy M, Inteeworn N, Stalder D, Streit B, Ganapathipillai S, Aebersold D M, Berthou S, Kaser-Hotz B, Gassmann M, Rohrer Bley C, Wergin M, Roos M, Höpfl G, Ohlerth S, Allal A S, Behrensmeier F, Thürlimann Beat, Carbone A, Crivellari D, Collins J, Gol-Ouh R, Lindtner J, Holmberg S B, Rudenstam C-M, Castiglione-Gertsch M, Price K N, Nasi M L, Bonetti M, Simoncini E, Fey M F, Bortoluzzi L, Weitzel M, Kranzbuehler H, Becker M, Taussky D, Azria D, Mirimanoff R O, Kramar A, Jeanneret Sozzi W, Goldhirsch A, Coates A S, Gelber R D, Ueltschi G, Lippold B, Kranzbühler H, Bernier J, Studer G, Landmann Ch, Mahler F, Greiner R, Taverna C, Stanek N, Ciernik I F, Friedrich E E, Beer K T, Balmer Majno S, Hügli A, Gallino A, Juelke Peter D, Pajic B, Curschmann J, Bieri S, Luthi J C, Suleiman M, Bargetzi M, Notter M, Thum Peter, Resink Therese Josephine, Erne Paul, Jamshidi Peiman, Hafner Hans-Peter, Mach N
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
Joss R, Stahel R, Martinelli G, Cerny T, Thürlimann B, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8.
01.01.1995Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
01.01.1995Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8
Joss R A, Stahel R, Martinelli G, Cerny T, Thürlimann Beat, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C